公开(公告)号：US20150284410A1

公开(公告)日：2015-10-08

申请号：US14742907

申请日：2015-06-18

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat ACHIRON ,  Roi Mashiach ,  Michael Gurevich

IPC: C07D513/14 ,  C12Q1/68

CPC classification number: A61K31/551 ,  C07D513/14 ,  C12Q1/6876 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A50/414

Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.

Abstract translation: 提供能够抑制RNA聚合酶I的活性的新化合物及其在治疗由RNA聚合酶I调节的疾病或病症中的用途，优选自身免疫性疾病如多发性硬化和增殖性疾病。

公开(公告)号：US10738361B2

公开(公告)日：2020-08-11

申请号：US15626229

申请日：2017-06-19

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat Achiron ,  Michael Gurevich

IPC: C12Q1/68 ,  C12Q1/6883

Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.

公开(公告)号：US09758831B2

公开(公告)日：2017-09-12

申请号：US14703942

申请日：2015-05-05

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat Achiron ,  Michael Gurevich

IPC: C12N15/11 ,  C12N15/12 ,  C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/166

Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.

公开(公告)号：US09688697B2

公开(公告)日：2017-06-27

申请号：US14742907

申请日：2015-06-18

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat Achiron ,  Roi Mashiach ,  Michael Gurevich

IPC: A61K31/55 ,  C07D471/12 ,  C07D513/14 ,  A61K31/551 ,  C12Q1/68

CPC classification number: A61K31/551 ,  C07D513/14 ,  C12Q1/6876 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A50/414

Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.

公开(公告)号：US20180264002A1

公开(公告)日：2018-09-20

申请号：US15996544

申请日：2018-06-04

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat Achiron ,  Roi Mashiach ,  Michael Gurevich

IPC: A61K31/551

CPC classification number: A61K31/551 ,  C07D513/14 ,  C12Q1/6876 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A50/414

Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.

公开(公告)号：US10022382B2

公开(公告)日：2018-07-17

申请号：US15626198

申请日：2017-06-19

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat Achiron ,  Roi Mashiach ,  Michael Gurevich

IPC: A61K31/551 ,  C07D471/12 ,  C07D513/14

Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.

公开(公告)号：US10993948B2

公开(公告)日：2021-05-04

申请号：US15996544

申请日：2018-06-04

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Anat Achiron ,  Roi Mashiach ,  Michael Gurevich

IPC: A61K31/551 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/4748 ,  C07D413/14 ,  C07D471/12 ,  C07D513/14 ,  C12Q1/6876

Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.